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ABSTRACT
Introduction In the multisystem inflammatory disorder 
systemic sclerosis (SSc), gastrointestinal tract (GIT) 
affliction is highly prevalent. There are no known 
disease modifying therapies and the negative impact 
is substantial. Aiming for a new therapeutic principle, 
and inspired by recent work showing associations 
between gut microbiota changes and GIT symptoms in 
SSc, we performed a pilot study on faecal microbiota 
transplantation (FMT) with the single- donor bacterial 
culture ‘Anaerobic Cultivated Human Intestinal 
Microbiome (ACHIM)’. Motivated by positive pilot study 
signals, we designed the ReSScue trial as a phase 
II multicentre, placebo- controlled, randomised 20- 
week trial to evaluate safety and efficacy on lower GIT 
symptoms of FMT by ACHIM in SSc.
Methods and analyses We aim to include 70 SSc 
participants with moderate to severe lower GIT 
symptoms, defined by the validated patient- reported 
University of California Los Angeles Scleroderma 
Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The 
trial includes three parts. In part A1 (induction phase) 
lasting from week 0 to week 12, participants will be 
randomised 1:1 to repeat infusions of 30 mL ACHIM or 
placebo at week 0 and 2 by gastroduodenoscopy. In 
part A2, which is an 8- week subsequent maintenance 
phase, all study participants will receive 30 mL ACHIM 
at week 12 and followed until week 20 on continued 
blind. In part B, which will last until the last participant 
completes part A2, the participants will be followed 
through a maximum 16- week extended monitoring 
period, for longer- term data on safety and intervention 
effects. Primary endpoint is change from baseline to 
week 12 in UCLA GIT subscale scores of diarrhoea or 
bloating, depending on the worst symptom at baseline 
evaluated separately for each patient. Secondary 
endpoints are safety measures and changes in UCLA 
GIT scores (total, diarrhoea and bloating).
Ethics and dissemination This protocol was approved 
by the Northern Norwegian Committee for Medical Ethics. 
Study findings will be published.
Trial registration number NCT04300426; Pre- results.
Protocol version V.3.1.
INTRODUCTION
Systemic sclerosis (SSc) is a rare, multiorgan 
system disorder with a marked negative 
impact on quality of life and reduced survival, 
with gastrointestinal tract (GIT) involvement 
as a major contributor to both.1–5 There are 
no specific therapies available for SSc- related 
GIT disease, but symptomatic relief can be 
provided by some agents, including proton 
pump inhibitors.3 6 7 Understanding of mech-
anisms behind SSc- related GIT disease is 
poor. However, it is known that alterations 
of the gut microbiota (dysbiosis) exist in SSc 
and associate with specific GIT symptoms. 
However, the question of how these alter-
ations affect the pathogenesis of this disease 
and correlate with SSc symptoms still remains. 
In terms of GIT symptoms, there is evidence 
Strengths and limitations of this study
 ► This study is a randomised clinical trial.
 ► The feasibility of reproduction is high due to the 
use of Anaerobic Cultivated Human Intestinal 
Microbiome.
 ► Long- term safety data will be available.
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that altered abundance of certain genera is associated 
with a reduction or increase in specific GIT symptoms.8–10 
This provides a rationale for manipulation of the patient’s 
gut microbiota with the intention of attaining therapeutic 
effects.8–10 Faecal microbiota transplantation (FMT) is 
currently applied as a therapeutic intervention strategy 
for targeting of gut bacteria in human diseases.11 We 
hypothesise that FMT is a strategy to be further explored 
in SSc patients and that intervention by Anaerobic Culti-
vated Human Intestinal Microbiome (ACHIM) in patients 
with SSc reduces lower GIT symptoms and GIT disease 
processes through direct effects on the gut microbiome 
composition and indirect effects on immune networks. 
We also hypothesise effects on other disease processes 
driven by constituents of the SSc gut microbiome.12
Evidence supporting the concept of FMT for thera-
peutic purposes comes mainly from relapsing Clostridioides 
difficile colitis. Early phase controlled studies indicated 
improved efficacy of FMT by faeces from random healthy 
donors compared with standard treatment by antibiotics.13 
FMT with healthy donor faeces has also shown promise in 
complex GIT disorders, such as the inflammatory bowel 
diseases and irritable bowel syndrome (IBS).11 14 It is also 
under investigation in many other disorders, including 
a range of metabolic conditions.11 It appears that clin-
ical efficacy is highly dependent on the properties of the 
donor faeces in most studied diseases, at the same time 
limiting possibilities for reproducibility.11 In general, 
it appears that FMT is well tolerated, but several safety 
issues remain unresolved, such as the potential cotransfer 
of resistant bacteria and viruses.15 16 Recently, concerns 
were raised by a report showing that two immune- 
compromised patients had contracted drug- resistant E. 
coli from donor faeces, with lethal outcome in one of 
them.17 These safety issues, as well as donor variation is 
feasible to overcome by replacing donor faeces with stan-
dardised in vitro cultivated bacterial ecosystems. Products 
of this type are available, such as the ACHIM, which was 
originally derived from faeces of a single healthy Norwe-
gian donor.14 ACHIM is cultivated in vitro under strictly 
anaerobic conditions, with maintained stability of bacte-
rial species composition. Clinically, it appears that the 
efficacy of FMT by ACHIM in C. difficile colitis is compa-
rable to that of FMT by fresh random donor feces.18 Of 
notice, and of special interest in times of the ongoing 
COVID-19 pandemic, ACHIM has due to repeated recul-
tivation using media selecting for bacteria without using 
any human components been tested to be free of human 
materials, known viruses and bacterial resistance genes, 
and has been so for the past two decades.19 Work is in 
progress to develop protocols for regular screening of 
known pathogens in donor faeces to be applied for FMT. 
But as the COVID-19 pandemic illustrates, it may not be 
possible to identify all potential human pathogens in 
fresh human faeces before it is given to patients.12 19
It is in general challenging to perform and interpret 
clinical trials in a rare, complex and heterogeneous 
disorder like SSc. Additionally, for an FMT trial with 
donor faeces, there are specific challenges with response 
evaluation, not only due to marked inter- patient varia-
tions in extent and severity of GIT symptoms at baseline, 
but also to differences in faecal microbiota composition 
between donors, evaluated by bacterial gene sequencing.9 
Thus, when we set up the first FMT pilot trial in SSc, we 
decided to standardise the intervention by using ACHIM. 
This allowed for (1) repeat, identical FMT across the 
active intervention group, (2) possibilities for systematic 
tracking of donor microbiome across the intervention 
group and importantly (3) possibility for independent 
trial replications.20
In SSc, there are no clinical disease activity indices 
that include GIT parameters, and no data on defined 
GIT outcomes from any SSc intervention study.21 Thus, 
for the FMT by ACHIM pilot trial it was not possible to 
benchmark GIT endpoints against previous interven-
tion studies.20 Therefore, we had to develop a primary 
endpoint, with rationale for it derived from observa-
tional studies. We chose the patient- reported outcome 
measure (PROM) ‘University of California Los Angeles 
Scleroderma Clinical Trial Consortium GIT 2.0’ (UCLA 
GIT) questionnaire.22 This PROM was developed for 
cross- sectional and longitudinal assessment of severity 
and impact of GIT symptoms in SSc and has been tested 
in recent clinical trials. It was therefore relevant for the 
purpose of the pilot trial.22 23
The UCLA GIT assesses GIT symptom severity in SSc by 
34 items in seven multi- item scales. Five of the scale scores 
(reflux, bloating, diarrhoea, faecal soilage and consti-
pation) grade severity of upper and lower GI symptom. 
The two last assess impact of GI symptoms on emotional 
well- being and social participation.22 For the pilot trial 
it was important that the UCLA GIT was equipped with 
definitions of minimally clinically important differences 
(MCIDs) for all scale scores included in the total score, 
and that the score was validated for the Norwegian 
language.22 23
The results from the pilot indicated that FMT by intes-
tinal ACHIM was safe and induced short- term meaningful 
clinical effects of on the UCLA lower GIT symptom scale 
scores ‘bloating’ and ‘diarrhoea’. This provided the ratio-
nale for further investigations of FMT by ACHIMs safety 
and efficacy in patients with lower GIT involvement in 
SSc.20
The pilot trial results indicated that effects of ACHIM 
waned over time.20 This is in line with findings from trials 
in relapsing C. difficile colitis and IBS where responses 
to FMT peaked after days, lasted for 8–12 weeks and 
then tended to decrease.24 These findings fit the notion 
that gut microbiota in many chronic diseases states is 
set to a state of dysbiosis; and will return to this state 
some time after cessation of intervention.25 Therefore, 
it appears the rationale to design FMT protocols for 
chronic diseases with an induction therapy phase aiming 
for rapid ‘normalisation’ of the patient’s gut microbiota, 
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Ideally, one should assess safety and efficacy of FMT 
induction and FMT maintenance in SSc in separate 
controlled trials. But due to the limited number of 
eligible SSc patients in Norway, this remains challenging. 
Therefore, we designed ReSScue with two sequential 
phases. First, a 12- week induction phase (part A1) with 
repeat intestinal infusions, followed by an 8- week mainte-
nance phase (part A2) with a single intestinal infusion of 
ACHIM at week 12 in all study participants (figure 1A). 
Additionally, we plan to follow all participants for a 
maximum 16 weeks until the last patient completes the 
20 weeks (part B) to obtain longer- term data on safety 
and durability of the effects (figure 1B).26–28 Impor-
tantly, we maintain the initial induction phase blind for 
all participants until the end of the study. Study end is 
defined as the time point when the last study participant 
has completed the last study visit at the end of the 20- week 
study period. By keeping the blind, we will be able to 
provide pilot data indicating if a single ACHIM infusion 
is sufficient as stand- alone therapy for lower GIT symp-
toms, or need to be combined with induction by repeat 
intestinal infusions.
Originally, we designed the ReSScue study with two 
modes of FMT delivery: (1) FMT by intestinal infusions 
in the induction phase (A1) and (2) FMT by daily doses 
of oral ACHIM capsules for the maintenance phase. The 
rationale for this approach was that oral capsules would 
be easier to administrate than intestinal infusions and 
transferable to daily clinical practice. Moreover, based on 
results from C. difficile colitis studies, we hypothesised that 
clinical efficacy of per oral capsules would not be inferior 
to intestinal infusions.29 Unfortunately, the production 
line for oral ACHIM capsules will not be ready in time for 
the ReSScue trial, but should be available for later studies.
The effects of FMT by ACHIM is presumably mediated 
through direct effects on the patient’s gut microbiome 
composition, and possibly also through indirect effects 
on immune networks, with the potential for clinical 
effects outside the GIT.30 We, thus, hypothesise that inter-
vention by ACHIM in SSc patients will result in clinically 
meaningful improvement of patient reported lower GIT 
symptoms, compared with placebo, and have effects on 




The ReSScue trial is a multicentre Phase II, randomised, 
double- blind placebo- controlled 20- week study consisting 
of three parts including 70 SSc participants (figure 1). 
It is an investigator initiated RCT with the Oslo Univer-
sity Hospital as the sponsor (affiliation No 1). The study 
consists of a 4–12 week screening period, a 12- week induc-
tion phase (part A1), with 1:1 randomised, double- blind 
parallel group interventions by endoscopic infusions of 
ACHIM or placebo at weeks 0 and 2, and an 8- week main-
tenance phase (part A2) where all participants receive one 
single open label endoscopic infusion of ACHIM at week 
12 (figure 1A). Additionally, we will follow all participants 
for a maximum 16 weeks monitoring period until the last 
patient completes the study (Part B) to obtain longer- 
term data on safety and durability of intervention effects 
(figure 1B).27 28 We used the Standard Protocol Items: 
Recommendations for Interventional Trials reporting 
guidelines.31
Study setting
The study will be performed at four university hospitals in 
Norway. Participants for the study will be recruited from 
the entire SSc population in Norway, with study inclusion 
regulated by the trial eligibility criteria explained below. 
Participant recruitment, eligibility screening, retrieval of 
informed consent and data collection will be performed 
at the four ReSScue study sites. Dietary habits at time of 
inclusion and at every study visits are recorded.
Objectives
The primary objective of this trial is to estimate efficacy of 
intestinal ACHIM infusions compared with placebo infu-
sions on lower GIT symptoms. This is measured by change 
from baseline to week 12 in UCLA GIT scale scores of 
diarrhoea or bloating, depending on the worst symptom 
at screening. The trial is set up with four secondary objec-
tives, including safety objectives focusing on tolerability 
of FMT by ACHIM and additional GIT measures.
Eligibility criteria
Detailed eligibility criteria are listed in online 
supplemental.
The major inclusion criteria are:
 ► Females and Males with age 18 to 85 years.
Figure 1 ReSScue study schematic with overall trial design 
and on participant level (A) overall trial design (B) trial design 
on participant level. ACHIM, Anaerobic Cultivated Human 
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 ► Fulfilment of the 2013 ACR/EULAR classification 
criteria for SSc.
 ► Ability to understand and follow trial procedures 
including completion of questionnaires regarding 
PROMs, such as the UCLA GIT score.
 ► Presence of moderate to severe SSc- related lower GI 
symptoms at time of inclusion, as defined by above 
threshold UCLA GIT score values for bloating and/
or diarrhoea.
The major exclusion criteria are:
 ► End- stage organ disease, including cardiovascular 
disease, lung disease, pulmonary hypertension, gastro-
intestinal conditions, renal insufficiency.
 ► Antibiotic therapy within 3 months of visit 1.
 ► Prednisone >10 mg/day within 4 weeks, and cyclo-
phosphamide or rituximab treatment within 6 months 
prior to visit 1.
 ► Unstable background therapy with; mycophenolate 
mofetil/sodium, methotrexate, azathioprine, tocili-
zumab, abatacept, leflunomide, tacrolimus, tofac-
itinib and cyclosporine A (see online supplemental 
for details).
Interventions
In part A1, eligible patients will be randomised 1:1 to 
receive 30 mL ACHIM or placebo, administered as 
duodenal infusions by upper endoscopy at weeks 0 and 
2. In part A2, all the study participants will receive 30 mL 
ACHIM, administered as duodenal infusions by upper 
endoscopy at week 12 (figure 1). Both study interventions 
will be provided in dark, sealed tubes ensuring similar 
appearance of placebo and ACHIM.
Outcomes
This study is designed with primary endpoint, defined 
by change from baseline to week 12 in the worst of the 
two UCLA GIT scale scores ‘diarrhoea’ or ‘bloating’ 
(table 1).22 Worst symptom is decided individually for 
each patient based on the screening visit GIT scale score 
values. As the two scores are measured on different scales, 
the diarrhoea score is rescaled into equivalent scale by 
multiplying it by 1.5. The subscale with the highest 
(rescaled) score is defined as the worst symptom. In case 
of equal scores for bloating and diarrhoea at screening, 
diarrhoea is chosen as the predominant symptom. If only 
one of the scores is available at screening, then that is 
used as the worst symptom.
Secondary endpoints include safety measures as well as 
‘total and scale scores diarrhoea and bloating’ assessed by 
the UCLA GIT score. Safety and tolerability of FMT will be 
assessed by adverse event (AE) monitoring, physical exam-
ination, vital signs and clinical laboratory testing from base-
line to the end of the study at week 20.
As the scientific rationale for intervention studies in 
SSc is limited by insufficient understanding of disease 
mechanisms, we plan ReSScue as a proof- of- concept 
study. The study is designed with repeated samplings of 
biospecimens including faeces, urine, blood, salvia and 
skin samples. This allows for broad range of explorative 
biomedical endpoints during study parts A1 and A2 and 
part B, and later development of research studies at 
molecular level.
The primary and secondary efficacy objectives will 
be evaluated the end of part A1 at week 12. Secondary 
safety endpoints and explorative clinical endpoints will be 
assessed at weeks 12 and 20 and partly 36.
Participant timeline
ReSScue is designed with one visit over a maximum 12- week 
screening period and a 12- week induction phase (part A1) 
with five visits at week 0, 2, 4, 6 and 12 (table 2). The mainte-
nance phase (part A2) is an 8 weeks phase with three visits at 
week 14, 16 and 20 (table 2). Patients completing part A will 
go over to the monitoring phase (part B) with a maximum 
of additional 16 weeks, or until the last patient reaches 20 
weeks of part A2. The phase consists of maximum four visits 
at week 24, 28, 32 and 36 (figure 1A,B).
Sample size
Based on power calculations for the primary endpoint 
‘change in worst symptom from baseline to week 12’, we 
plan to enrol in total approximately 70 adult Norwegian 
patients with SSc at the four ReSScue sites. Assumptions 
on the MCIDs and SD of the GIT scale scores diarrhoea 
and bloating used in the calculation are adopted from 
Khanna et al.23 However, in contrast to the validation 
study that was based on two assessments of UCLA GIT 
score, this study will assess UCLA GIT score four times 
before baseline and five times during the study part A1. 
Thus, it can be argued that this study has better control 
over the variance, and the assumption on the SD used is 
potentially conservative. A sample size of approximately 
N=64 patients, n=32 patients per ACHIM/placebo arm, 
is expected to achieve a power of 80% of detecting a 
change in mean (p<0.05, two sided) of −0.50 (or higher) 
if the relating SD would be 0.70 (or lower). Considering a 
dropout rate of 10%, a total of approximately 70 patients 
will be enrolled in the study.
Recruitment
Recruitment of participants has started in September 
2020. Study inclusion started 28 September 2020 and will 
end 30 April 2022.
Assignment of interventions
Based on previous data on the same patient popula-
tion, the proportions of the worst lower GIT symptoms 
in patients with SSc are not equal; 40% patients having 
diarrhoea, and 60% bloating as worst symptom. To ensure 
equal allocation of different symptoms to each inter-
vention group, a stratified randomisation procedure is 
implemented. Participants are first grouped into strata 
according to the worst symptom (diarrhoea/bloating), 
and then assigned to an intervention according to sepa-
rate randomisation schedules within each stratum. Worst 
symptom is decided individually based on the screening 
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On day 1, the study participants will be assigned a 
unique number (randomisation number) in ascending 
numerical order at the Oslo University Hospital (OUH). 
The randomisation number encodes the participant’s 
assignment to the two intervention arms in study part 
A1 according to the randomisation schedule generated 
prior to the study by statisticians at the OUH study site 
and entered in the same web- based solution as the elec-
tronic case report forms (eCRF). Each participant will 
be dispensed blinded study intervention, labelled with 
his/her unique randomisation number, throughout the 
12- week study.
Table 1 Efficacy endpoints in all study parts
Endpoints
Primary Change from baseline to week 12 in UCLA GIT score items diarrhoea or bloating, depending which was the 
worst symptom at the baseline evaluated separately for each patient.
Secondary Safety and tolerability assessed by adverse event (AE) monitoring, physical examination and clinical 
laboratory testing from baseline to the end of the study period
Change from baseline to week 12 in total UCLA GIT score
Change from baseline to week 12 in UCLA GIT score item diarrhoea
Change from baseline to week 12 in UCLA GIT score item bloating
Other outcome 
measures
Change from baseline to week 12 in Faecal incontinence quality of life scale
Change from baseline to week 12 in UCLA GIT score item reflux
Change from baseline to week 12 in UCLA GIT score item faecal soilage
Change from baseline to week 12 in UCLA GIT score item constipation
Change from baseline to week 12 in UCLA GIT score item emotional well- being
Change from baseline to week 12 in UCLA GIT score item social participation
Change from baseline to week 12 in • Change from baseline to week 12 in HAQ- DI scores
Change from baseline to week 12 in VAS Fatigue scale
Change from baseline to week 12 in ScleroId score
Change from baseline to weeks 2, 6 and 12 in overall faecal microbiome composition measured by 16sRNA 
based methods
Change from baseline to week 12 in saliva, skin and urine microbiome measured by 16sRNA based 
methods
Change from baseline to weeks 2, 6 and 12 in immunoglobulin bound fraction of the overall faecal 
microbiome
Change from baseline to week 12 in GIT time and contractions evaluated by SmartPill technology along 
with registration of stool frequency and consistency by Bristol Stool Scale
Change from baseline to weeks 6 and 12 in peripheral blood B cell and T cells (as evaluated by receptor 
sequencing, proteomics and cellular phenotyping) and content of soluble molecules
Change from baseline to weeks 2 and 12 in the architecture and cellular composition of duodenal biopsy 
specimens (including characterisation of cellular surface markers, proteomics, metabolomics and immune 
cell receptor sequencing
Change from baseline to week 12 in skin properties evaluated by elastography and ultrasonographic skin 
thickness
Change from baseline to week 12 in Health- related quality of life assessed by EQ- 5D
Change from week 12 through week 20 in all participants, and up to week 36 in a subset of participants 
in UCLA GIT score item diarrhoea or bloating, depending which was the worst symptom at the baseline 
evaluated separately for each patient
Follow changes of UCLA total GIT score from week 12 through week 20 in all participants, and up to week 
36 in a subset of participants
Follow changes in mean of HAQ- DI; VAS Fatigue; ScleroId score; and patient reported global assessment 
from week 12 through week 20 in all participants, and up to week 36 in a subset of participants
Assess changes of overall faecal microbiome composition measured by 16sRNA- based methods from 
week 12 to week 20 in all participants, and up to week 36 in a subset of participants
Assess change of saliva, skin and urine microbiome measured by 16sRNA based methods from week 12 to 
week 20 in all participants
Assess change in peripheral blood B cell and T cells and content of soluble molecules from week 12 to 
week 20 in all participants, and up to week 36 in a subset of participants
Assess changes in upper GIT scores from week 12 to 20 and determine potential associations to the 
architecture and cellular composition of oesophagus biopsy specimens
Assess change from week 12 to 20 in Health- related Quality of Life assessed by EQ- 5D from week 12 to 
week 20 in all participants, and up to week 36 in a subset of participants
EQ5D, EuroQoL 5L - health- related quality of life; HAQ- DI, 1qHealth Assessment Questionnaire- Disability Index; UCLA GIT, University of 
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After completion of the part A1, 12- week double- 
blinded study, the participant’s randomisation number 
will remain blinded throughout part A2. Unblinding of 
the randomisation number will not be performed before 
all the participants have completed the 20 weeks ReSScue 
trial study period and data have been locked.
Data collection, management
Data recording will follow the Good Clinical Practice 
reporting guidelines. Data will be collected with eCRF. 
For this data recording and handling Viedoc, part of the 
NorCRIN structure, will be used. NorCRIN is the Norwe-
gian hub of a larger European research network, Euro-
pean Clinical Research Infrastructure Network. Patient 
specific modules with, that is, EQ- 5D already exist, the 
others will be developed in collaboration with the clin-
ical trial unit (CTU) at OUH. The investigators will have 
access to the final trial dataset without any limitations. 
Data management is provided from the CTU at OUH.
Statistical methods
Continuous primary endpoint ‘UCLA GIT scores of 
subscales diarrhoea or bloating’ is assessed four times 
during the screening period and five times during the 
study period A1 (at week 0, 2, 4, 6 and 12), and will be 
analysed using a linear mixed model accounting for the 
correlations between repeated measurements within each 
participant by random intercept and slope. The interven-
tion group slope, stratification factor (worst symptom) 
and intervention*time- interaction will be treated as 
fixed effects in the model. In addition, the model will 
be adjusted for the baseline value of the patient specific 
worst symptom.
The continuous secondary endpoints ‘total UCLA GIT 
score’, ‘UCLA GIT scale score diarrhoea’ and ‘UCLA 
GIT scale score bloating’ will be analysed exploiting the 
repeated measurements at nine time points (four during 
the screening period and five at weeks 0, 2, 4, 6 and 12) by 
using a linear mixed model with the intervention group, 
stratification factor and intervention*time- interaction as 
fixed effects and a random intercept and slope.
For safety, summary tables will be created for all safety 
information. All site- reported AEs will also be grouped 
by seriousness, primary relationship (intervention, unre-
lated and unknown) and timing of onset (preinterven-
tion and postintervention).
Data monitoring
An independent data monitoring committee (DMC) is 
established, following good standard DMC guidelines 
which includes insights to blinded and unblinded data. 
The DMC contains a SSc expert, a gastroenterologist with 
FMT expertise and a statistician. Safety concerns will be 
discussed in the DMC which meets on a regular basis.
The intensity of AEs will be rated by the investigators 
as mild (easily tolerated), moderate (enough discom-
fort to cause interference with usual activity) or severe 
(incapacitating or causing inability to work or to perform 
usual activities). AEs of gastrointestinal perforation and 
laryngospasm due to gastro- duodenoscopy are of special 
interest, due to previous occurrence in the pilot trial. 
Patients will be observed at our dedicated clinical trial 
department after each gastroduodenoscopy for these 
possible AEs and assessed accordingly if symptoms appear.
Patient and public involvement statement
Patient representatives from the Norwegian Rheuma-
tology Foundation have been involved in the study 
protocol development, obtaining funding and will be 
involved in the conduction of the trial.
ETHICS AND DISSEMINATION
The trial is being conducted in compliance with the 
protocol, the ethical principles laid down in the Declara-
tion of Helsinki and in accordance with the International 
Conference on Harmonisation Tripartite Guideline for 
Good Clinical Practice. All patients will provide written 
informed consent prior to trial entry. The study has 
been approved by the Regional Committee of Health 
and Medical Research Ethics in Northern Norway (No. 
2016/1529) and the Norwegian Medical Agency (Statens 
legemiddelverk) (20/02597–21). Study findings will be 
shared at conferences and as published manuscripts; and 
made available to interested participants. No medical 
writers will be used.
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